MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fendo.2025.1669613

Медицинская библиотека · Frontiers in endocrinology · 2025

Comparative effectiveness of empagliflozin versus dapagliflozin in adults with metabolic dysfunction-associated steatotic liver disease.

Wu Jheng-Yan, Tu Yu-Kuan, Kuo Chia-Chih, Liu Mei-Yuan, Hsu Wan-Hsuan, Tsai Ya-Wen, Liu Ting-Hui, Huang Po-Yu, Chuang Min-Hsiang, Hung Kuo-Chuan, Yu Tsung, Liao Kuang-Ming, Lai Chih-Cheng

СтатьяСравнительное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Sodium-glucose co-transporter-2 inhibitors (SGLT2is) show promise in treating metabolic dysfunction-associated steatotic liver disease (MASLD). However, the relative efficacy of different SGLT2is remains unclear. We aimed to compare the clinical effectiveness of empagliflozin versus dapagliflozin in adults with MASLD.

METHODS

Using the TriNetX database, we conducted a retrospective cohort study of adults with MASLD who were newly prescribed either empagliflozin or dapagliflozin between January 2013 and September 2024. After propensity score matching, we compared 13,274 patients in each group. The primary outcome was a composite of all-cause hospitalization, all-cause mortality, major adverse cardiovascular events (MACEs), major adverse kidney events (MAKEs), and decompensated hepatic events. Secondary outcomes included each individual component of the primary outcome.

RESULTS

Empagliflozin was associated with a lower risk of primary composite outcomes compared to dapagliflozin (HR, 0.84; 95% CI, 0.80-0.88). This benefit was consistent across most subgroups, including sex, presence of liver cirrhosis, heart failure, T2DM, and chronic kidney disease. Significant interactions were observed for age groups (p=0.04) and borderline for BMI categories (p=0.06). Empagliflozin also showed lower risks for all-cause hospitalization (HR, 0.84; 95% CI, 0.79-0.88), all-cause mortality (HR, 0.79; 95% CI, 0.66-0.96), MACE (HR, 0.88; 95% CI, 0.78-0.99), and MAKE (HR, 0.63; 95% CI, 0.47-0.86), but no difference in decompensated hepatic events (HR, 1.01; 95% CI, 0.81-1.27).

CONCLUSIONS

In patients with MASLD, empagliflozin was associated with better clinical outcomes compared to dapagliflozin, particularly in reducing cardiovascular and renal events, hospitalizations, and mortality.

Для цитирования: Wu Jheng-Yan, Tu Yu-Kuan, Kuo Chia-Chih, Liu Mei-Yuan, Hsu Wan-Hsuan, Tsai Ya-Wen, Liu Ting-Hui, Huang Po-Yu, Chuang Min-Hsiang, Hung Kuo-Chuan, Yu Tsung, Liao Kuang-Ming, Lai Chih-Cheng. Comparative effectiveness of empagliflozin versus dapagliflozin in adults with metabolic dysfunction-associated steatotic liver disease.. Frontiers in endocrinology. 2025. DOI: 10.3389/fendo.2025.1669613.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.